CLL and COVID-19: light at the end of the tunnel?
Ontology highlight
ABSTRACT:
SUBMITTER: Scarfo L
PROVIDER: S-EPMC9352187 | biostudies-literature | 2022 Aug
REPOSITORIES: biostudies-literature
Publications
Similar Datasets
Project description: Not available
| S-EPMC7834488 | biostudies-literature
Project description: Not available
| S-EPMC10238449 | biostudies-literature
Project description:Anthracycline-induced cardiotoxicity (AIC) is a serious and common side effect of anthracycline therapy. Identification of genes and genetic variants associated with AIC risk has clinical potential as a cardiotoxicity predictive tool and to allow the development of personalized therapies. In this review, we provide an overview of the function of known AIC genes identified by association studies and categorize them based on their mechanistic implication in AIC. We also discuss the importance of functional validation of AIC-associated variants in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to advance the implementation of genetic predictive biomarkers. Finally, we review how patient-specific hiPSC-CMs can be used to identify novel patient-relevant functional targets and for the discovery of cardioprotectant drugs to prevent AIC. Implementation of functional validation and use of hiPSC-CMs for drug discovery will identify the next generation of highly effective and personalized cardioprotectants and accelerate the inclusion of approved AIC biomarkers into clinical practice.
| S-EPMC11260185 | biostudies-literature
Project description:RationaleCountries worldwide rely on the COVID-19 vaccine to contain the spread of the pandemic. However, because of the inequality in distribution, people in many demographic groups and regions still do not have access to a safe and effective COVID-19 vaccine.ObjectiveTo aid vaccine promotion campaigns that target populations with different access to the COVID-19 vaccine, this study examined how vaccine availability and vaccination intention influence people's consideration of the COVID-19 vaccine.MethodWe conducted a two-wave longitudinal survey and choice-based conjoint experiment to examine the influence of vaccine availability and vaccination intention on perceived barriers of vaccination (e.g., safety and cost concern) and preference in different vaccine features (e.g., FDA approval status and number of doses administered).ResultWe found that low availability and intention increased attention to global behavioral barriers such as safety concern and high-level vaccine attributes such as efficacy. In contrast, high availability articulates practical considerations such as cost and logistics associated with vaccination.ConclusionBased on such findings, we conclude that health communicators need to strategically customize their messages based on audience access to the COVID-19 vaccine and their intention to get vaccinated. Highlighting the safety and effectiveness of the vaccine may be more effective in low-accessibility and low-intention groups, while emphasis on practical considerations such as vaccine cost and logistics may be more effective in high-accessibility and high-intention groups.
| S-EPMC8364891 | biostudies-literature
Project description: Not available
| S-EPMC10432298 | biostudies-literature
Project description:Richter transformation (RT) represents an uncommon (2% to 10%) but feared complication of chronic lymphocytic leukemia (CLL). The disease is characterized by rapid disease kinetics, a high-risk genetic mutational profile, chemoimmunotherapy resistance, and consequent poor survival. The typical overall survival (OS) from the pre-Bruton tyrosine kinase (BTK)/B-cell lymphoma 2 (BCL2) inhibitor CLL era is 6-12 months, and recent series of RT complicating progression on a BTK or BCL2 inhibitor in heavily pretreated relapsed CLL patients suggests an OS of only 3-4 months. Despite these sobering survival statistics, novel agents have the potential to impact the natural RT disease course. This article reviews recent therapeutic developments, focusing on inhibitors of BTK, BCL2, the PD1-PDL1 axis, and T-cell-activating/engaging therapies. Herein, I discuss the importance of randomized clinical trials in a disease where small single-arm studies dominate; industry engagement, including the role of registrational studies; and the need to integrate prospectively planned correlative biological studies embedded within future clinical trials to help discover which patient benefits most from each class or combination of novel targets.
| S-EPMC10727096 | biostudies-literature
Project description: Not available
| S-EPMC9872807 | biostudies-literature
Project description:Nonalcoholic steatohepatitis (NASH) is a chronic liver disease affecting a large population worldwide. No clinically approved drugs are available. In this minireview, we discuss the heterogeneous nature of NASH and lack of consensus in outcome measures among clinical trials. We summarize NASH therapeutic targets and candidate drugs. We compare the efficacy of 33 published clinical trials that evaluated noninvasive biomarkers and liver biopsy. Currently, phase II trial results of fibroblast growth factor 21 (FGF21) and phase III trial results of resmetirom and pioglitazone are encouraging.
| S-EPMC10500295 | biostudies-literature
Project description:Immunotherapeutic treatment approaches are now an integral part of the treatment of many solid tumors. However, attempts to integrate immunotherapy into the treatment of prostate cancer have been disappointing so far. This is due to a highly immunosuppressive, "cold" tumor microenvironment, which is characterized, for example, by the absence of cytotoxic T cells, an increased number of myeloid-derived suppressor cells or regulatory T cells, a decreased number of tumor antigens, or a defect in antigen presentation. The consequence is a reduced efficacy of many established immunotherapeutic treatments such as checkpoint inhibitors. However, a growing understanding of the underlying mechanisms of tumor-immune system interactions raises hopes that immunotherapeutic strategies can be optimized in the future. The aim of this review is to provide an overview of the current status and future directions of immunotherapy development in prostate cancer. Background information on immune response and tumor microenvironment will help to better understand current therapeutic strategies under preclinical and clinical development.
| S-EPMC8910587 | biostudies-literature
Project description:Lung cancer is one of the most common and deadliest cancers in the world. The major socio-environmental risk factor involved in the development of lung cancer is cigarette smoking. Additionally, there are multiple genetic factors, which may also play a role in lung cancer risk. Early work focused on the presence of relatively prevalent but low-penetrance alterations in candidate genes leading to increased risk of lung cancer. Development of new technologies such as genomic profiling and genome-wide association studies has been helpful in the detection of new genetic variants likely involved in lung cancer risk. In this review, we discuss the role of multiple genetic variants and review their putative role in the risk of lung cancer. Identifying genetic biomarkers and patterns of genetic risk may be useful in the earlier detection and treatment of lung cancer patients.
| S-EPMC3581605 | biostudies-literature